Optic Neuritis - Pipeline Review - H2 2013





Published: October 2013 | Pages: 39 | Format: PDF

 Summary 

 Global Markets Direct’s, 'Optic Neuritis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Optic Neuritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Optic Neuritis. Optic Neuritis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. 

 Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. 

 Scope 

 

  •  A snapshot of the global therapeutic scenario for Optic Neuritis. 
  •  A review of the Optic Neuritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  •  Coverage of products based on various stages of development ranging from discovery till registration stages. 
  •  A feature on pipeline projects on the basis of monotherapy and combined therapeutics. 
  •  Coverage of the Optic Neuritis pipeline on the basis of route of administration and molecule type. 
  •  Key discontinued pipeline projects. 
  •  Latest news and deals relating to the products. 

 

 Reasons to buy 

 

  •  Identify and understand important and diverse types of therapeutics under development for Optic Neuritis. 
  •  Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  •  Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. 
  •  Devise corrective measures for pipeline projects by understanding Optic Neuritis pipeline depth and focus of Indication therapeutics. 
  •  Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. 
  •  Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. 

 

 Additional Information 

 Companies Mentioned 

 Biogen Idec Inc. 

 Teijin Pharma Limited 

 Neuralstem, Inc. 

 Artielle ImmunoTherapeutics, Inc. 

 Country 

 Global 

 Sector 

 Ophthalmology 

 Introduction 

 Global Markets Direct Report Coverage 

 Optic Neuritis Overview 

 Therapeutics Development 

 An Overview of Pipeline Products for Optic Neuritis 

 Optic Neuritis Therapeutics under Development by Companies 

 Optic Neuritis Therapeutics under Investigation by Universities/Institutes 

 Late Stage Products 

 Comparative Analysis 

 Mid Clinical Stage Products 

 Comparative Analysis 

 Discovery and Pre-Clinical Stage Products 

 Comparative Analysis 

 Optic Neuritis Therapeutics - Products under Development by Companies 

 Optic Neuritis Therapeutics - Products under Investigation by Universities/Institutes 

 Companies Involved in Optic Neuritis Therapeutics Development 

 Biogen Idec Inc. 

 Teijin Pharma Limited 

 Neuralstem, Inc. 

 Artielle ImmunoTherapeutics, Inc. 

 Optic Neuritis - Therapeutics Assessment 

 Assessment by Monotherapy Products 

 Assessment by Route of Administration 

 Assessment by Molecule Type 

 Drug Profiles 

 BIIB-033 - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 RTL For Optical Neuritis - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 NSI-566 - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 freeze-dried sulfonated human normal immunoglobulin - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 phenytoin - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 Optic Neuritis Therapeutics - Drug Profile Updates 

 Optic Neuritis Therapeutics - Discontinued Products 

 Appendix 

 Methodology 

 Coverage 

 Secondary Research 

 Primary Research 

 Expert Panel Validation 

 Contact Us 

 Disclaimer 

 List of Tables 

 Number of Products Under Development for Optic Neuritis, H2 2013 

 Products under Development for Optic Neuritis - Comparative Analysis, H2 2013 

 Number of Products under Development by Companies, H2 2013 

 Number of Products under Investigation by Universities/Institutes, H2 2013 

 Comparative Analysis by Late Stage Development, H2 2013 

 Comparative Analysis by Mid Clinical Stage Development, H2 2013 

 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 

 Products under Development by Companies, H2 2013 

 Products under Investigation by Universities/Institutes, H2 2013 

 Biogen Idec Inc., H2 2013 

 Teijin Pharma Limited, H2 2013 

 Neuralstem, Inc., H2 2013 

 Artielle ImmunoTherapeutics, Inc., H2 2013 

 Assessment by Monotherapy Products, H2 2013 

 Assessment by Stage and Route of Administration, H2 2013 

 Assessment by Stage and Molecule Type, H2 2013 

 Optic Neuritis Therapeutics - Drug Profile Updates 

 Optic Neuritis Therapeutics - Discontinued Products 

 List of Figures 

 Number of Products under Development for Optic Neuritis, H2 2013 

 Products under Development for Optic Neuritis - Comparative Analysis, H2 2013 

 Products under Development by Companies, H2 2013 

 Products under Investigation by Universities/Institutes, H2 2013 

 Late Stage Products, H2 2013 

 Mid Clinical Stage Products, H2 2013 

 Discovery and Pre-Clinical Stage Products, H2 2013 

 Assessment by Monotherapy Products, H2 2013 

 Assessment by Route of Administration, H2 2013 

 Assessment by Stage and Route of Administration, H2 2013 

 Assessment by Molecule Type, H2 2013 

 Assessment by Stage and Molecule Type, H2 2013